| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 09/18/2002 | CN1090936C Compound prepn. for curing acne |
| 09/18/2002 | CN1090935C Pharmaceutical compsn. of piperidnoalkanol compounds |
| 09/18/2002 | CN1090934C Prepn. of salts of pharmaceutical active substances which have acidic groups |
| 09/18/2002 | CN1090918C Silicone compsns. |
| 09/18/2002 | CA2403648A1 Use of organophosphorous compounds for producing a medicament for treating infections |
| 09/18/2002 | CA2403500A1 Substituted biphenyl derivatives |
| 09/17/2002 | US6452054 Psychological disorders |
| 09/17/2002 | US6452052 Such as bis-(2-(3-hydroxy-butyrylamido)phenyl)-disulfide; treating allergies of the eyes, nose, skin, ear, gastrointestinal tract, airways or lung and preventing/ treating systemic mastocytosis |
| 09/17/2002 | US6452039 Endothelin antagonist |
| 09/17/2002 | US6452037 Carbonylated, oligoanilinated derivatives; antitumor agents; photosensitizers transforming molecular oxygen into singlet oxygen; bioavailable |
| 09/17/2002 | US6452032 Organosilyl compounds having nuclear hormone receptor modulating activity |
| 09/17/2002 | US6452028 Vitamin D3 analogs |
| 09/17/2002 | US6452025 Three-step conversion of protected taxane ester to paclitaxel |
| 09/17/2002 | US6452015 Cyclobutaindolecarboxamide compounds |
| 09/17/2002 | US6452013 For treating conditions which are related to impairment of gastric emptying |
| 09/17/2002 | US6452011 Process for production of piperidine derivatives |
| 09/17/2002 | US6452007 Crystal forms of 1-[5-methanesulfonamidoindolyl-2-carbonyl]-4-[3-(1-methylethylamino)-2-pyridinyl]piperazine |
| 09/17/2002 | US6452005 JAK-3 inhibitors for treating allergic disorders |
| 09/17/2002 | US6452001 1,4-diazepine-2-one derivatives as neurokinin antagonist |
| 09/17/2002 | US6451994 Polypeptides, polynucleotides; drug screening; diagnosing alzheimer*s, parkinson*s, huntington*s, and creutzfelt-jacob disease; amyotrophic lateral sclerosis, cystic fibrosis |
| 09/17/2002 | US6451980 Antibody testing; obtain sample, incubate with binding particles, detect signal |
| 09/17/2002 | US6451973 Human immunodeficiency virus (hiv) protease inhibitors |
| 09/17/2002 | US6451971 Polypeptide cell adhesion inhibitors; antimetastasis and anticarcinogenic agents |
| 09/17/2002 | US6451968 Hoogsteen type base pairing in triplex motif; diagnosis; heat resistance; detection of point mutations, restriction enzyme sites, and transcription inhibition |
| 09/17/2002 | US6451861 Reduction of gastro-intestinal bacterial load |
| 09/17/2002 | US6451860 Methods for treating depression and other disorders using optically pure (−)-bupropion |
| 09/17/2002 | US6451859 C16 unsaturated FP-selective prostaglandins analogs |
| 09/17/2002 | US6451858 Certain 5-alkyl-2-arylaminophenylacetic acids and derivatives |
| 09/17/2002 | US6451857 Analgesic compositions comprising anti-epileptic compounds and methods of using same |
| 09/17/2002 | US6451854 α-amino acid phenyl ester derivatives |
| 09/17/2002 | US6451853 Small molecules that elicit a polarized Th1 response and for modulation of cellular immunity |
| 09/17/2002 | US6451851 Pharmaceutical composition with antiviral activity containing an hydroxymic acid derivative and an antiviral agent |
| 09/17/2002 | US6451850 Bio-chemical germanium complexes with high therapeutic efficiency and wide application spectrum |
| 09/17/2002 | US6451849 Use of hydroxymatairesinol for prevention of cancers, non-cancer, hormone dependent diseases and cardiovascular diseases by hydroxymatairesinol, and a pharmaceutical preparation, food additive and food product comprising hydroxymatairesinol |
| 09/17/2002 | US6451848 Compositions and methods comprising morphine gluconate |
| 09/17/2002 | US6451842 Cyclic amine derivatives and their use as drugs |
| 09/17/2002 | US6451840 Regulation of T cell-mediated immunity by tryptophan |
| 09/17/2002 | US6451839 Indole sPLA2 inhibitors |
| 09/17/2002 | US6451838 1-(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives |
| 09/17/2002 | US6451837 Neuroprotective effects of mitogen-activated protein kinase (MAPK) cascade inhibitors |
| 09/17/2002 | US6451836 Method of inhibiting liver glycogen phosphorylase with 2-alkylpyrrolidines |
| 09/17/2002 | US6451834 Indeno[1,2-c]-, naphtho[1,2-c]- and benzo[6,7]cyclohepta[1,2-c]pyrazole derivatives |
| 09/17/2002 | US6451831 Treatment with hydantoin derivative |
| 09/17/2002 | US6451829 Coumarinic compounds having IgE affecting properties |
| 09/17/2002 | US6451828 Selective inhibition of glutaminase by bis-thiadiazoles |
| 09/17/2002 | US6451827 2,3,5-substituted biphenyls useful in the treatment of insulin resistance and hyperglycemia |
| 09/17/2002 | US6451826 Optically pure (−) amlodipine compositions |
| 09/17/2002 | US6451825 Pharmaceutical agent containing Rho kinase inhibitor |
| 09/17/2002 | US6451824 Sulfonylaminocarboxylic acids |
| 09/17/2002 | US6451822 3-(Amino- or aminoalkyl)pyridinone derivatives and their use for the treatment of HIV related diseases |
| 09/17/2002 | US6451821 Use of 2-aminothiazoline derivatives as inhibitors of inducible no-synthase |
| 09/17/2002 | US6451819 Pyrrolidine-3-yl-sulfanyl, or sufonyl or sufinyl derivatives used in the treatment of neurodegenerative diseases |
| 09/17/2002 | US6451818 Therapeutic use of 1,6-dimethyl-8β-hydroxymethyl-10α-methoxyergoline |
| 09/17/2002 | US6451817 Alpha-substituted-1-benzyl-napthyls |
| 09/17/2002 | US6451816 Use of pyridyl alkane, pyridyl alkene and/or pyridyl alkine acid amides in the treatment of tumors or for immunosuppression |
| 09/17/2002 | US6451815 Method of enhancing bioavailability of fexofenadine and its derivatives |
| 09/17/2002 | US6451813 Treatment of gastroparesis in certain patient groups |
| 09/17/2002 | US6451812 Farnesyl protein transferase inhibitors for treating arthropathies |
| 09/17/2002 | US6451811 Herpes virus |
| 09/17/2002 | US6451810 Amide substituted imidazoquinolines |
| 09/17/2002 | US6451808 Inhibition of emetic effect of metformin with 5-HT3 receptor antagonists |
| 09/17/2002 | US6451807 Methods of treating sexual dysfunction in an individual suffering from a retinal disease, class 1 congestive heart failure, or myocardial infarction using a PDE5 inhibitor |
| 09/17/2002 | US6451806 Treating and/or preventing side effects including constipation, vomiting and nausea |
| 09/17/2002 | US6451804 Heteroalkylamino-substituted bicyclic nitrogen heterocycles |
| 09/17/2002 | US6451803 N-acyl and n-aroyl aralkyl amides useful in treating seritonergic disorders |
| 09/17/2002 | US6451802 S-oxide lipid lowering compounds |
| 09/17/2002 | US6451801 Compounds and methods for treatment of asthma, allergy and inflammatory disorders |
| 09/17/2002 | US6451799 1,4-dihydropyridine derivatives |
| 09/17/2002 | US6451796 Fused pyrazine compounds |
| 09/17/2002 | US6451795 Central neurodegenerative diseases |
| 09/17/2002 | US6451794 2,3-Diaryl-pyrazolo[1,5-b]pyridazines derivatives, their preparation and their use as cyclooxygenase 2(COX-2) inhibitors |
| 09/17/2002 | US6451792 Matrix metalloprotease inhibitors |
| 09/17/2002 | US6451791 Amidoaromatic ring sulfonamide hydroxamic acid compounds |
| 09/17/2002 | US6451789 Central nervous system disorders; cognition activators |
| 09/17/2002 | US6451788 Administering an antidepressant and a selected amino acid |
| 09/17/2002 | US6451787 Remedies for ocular diseases |
| 09/17/2002 | US6451786 Tyrosine kinase inhibitors |
| 09/17/2002 | US6451785 Beta lactams as antiproliferative agents |
| 09/17/2002 | US6451784 Inhaling carboplatin |
| 09/17/2002 | US6451783 Administering to an obese patient or a patient at risk of becoming obese therapeutically effective amount of compound that attenuates binding of agouti-related protein to melanocortin receptors |
| 09/17/2002 | US6451782 Use of 4-androstene-3alpha,17 beta-diol to increase testosterone levels in humans |
| 09/17/2002 | US6451781 Substituted acylguanidines, process for their preparation, their use as medicaments or diagnostics, and medicaments comprising them |
| 09/17/2002 | US6451780 Progesterone antagonists for the production of pharmaceutical agents for the treatment of dysfunctional uterine bleeding |
| 09/17/2002 | US6451779 Composition and method for contraception and treatment of tumors of the mammary glands |
| 09/17/2002 | US6451778 Oral contraceptive |
| 09/17/2002 | US6451777 Method for regulating hair growth |
| 09/17/2002 | US6451776 Water soluble prodrugs of hindered alcohols |
| 09/17/2002 | US6451775 Castor amidopropyl dimethyl phospholipids as emulsifiers |
| 09/17/2002 | US6451773 Composition for treating acneiform eruption containing: (a) a chitosan having a molecular weight ranging from about 500,000 to about 5,000,000 g/mole and a degree of deacylation greater than 80%; (b) an acid-form active ingredient for treating acne |
| 09/17/2002 | US6451771 Use of anabolic agents anti-catabolic agents and antioxidant agents for protection treatment and repair of connective tissues in humans and animals |
| 09/17/2002 | US6451770 A liquid jet intradermal administration apparatus that administers an immunogenic composition or vaccine to an animal: without a needle, and into the epidermis, dermis and/or hypodermis; wherein the apparatus includes an |
| 09/17/2002 | US6451768 Macrolide antiinfective agents |
| 09/17/2002 | US6451767 Treating restenosis, inhibiting angiogenesis in malignant tumor, sarcoma or neoplastic tissue |
| 09/17/2002 | US6451764 VEGF-related protein |
| 09/17/2002 | US6451761 N′N′-dichlorinated omega-amino acids and uses thereof |
| 09/17/2002 | US6451760 Treatment of inflammation using a 2F1 polypeptide or an antibody thereto |
| 09/17/2002 | US6451734 Acts as a desiccant and/or defoliant; halogenation at the 4 position; also for lowering the blood sugar level, hypoglycemic agent |
| 09/17/2002 | US6451605 Anise, calendula, quassia, rosemary, or sassafras volatile oil; alcohol and fatty ester emollient; lice insecticide |
| 09/17/2002 | US6451584 Nutrient broth for use in the propagation of preferential microorgansim and generation of foods |
| 09/17/2002 | US6451567 Growing of the microflora in fermentation medium containing nonchloride containing sodium salts, in particular sodium sulfate. the process produces microflora having a cell aggregate size useful for the production of food products for |